for people ages 1 month to 79 years (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Julia Chu, MD
Headshot of Julia Chu
Julia Chu



Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.

Funding Source: FDA OOPD

Official Title

A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients


Adenovirus, Primary Immune Deficiency Disorder, cytotoxic t-lymphocytes, Adenoviridae Infections, Primary Immunodeficiency Diseases, Immunologic Deficiency Syndromes


For people ages 1 month to 79 years

  1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:
    • Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or
    • clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR
    • Medical intolerance to anti-viral therapies including:
      • grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.

    Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs) Age: 0.1 to 79 years

    Females of childbearing potential with a negative urine pregnancy test

  2. Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus.
    1. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor > 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus.

    AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).

    AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.

  3. Patient exclusion criteria:

A patient meeting any of the following criteria is not eligible for the present study:

. Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients >16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.

Known hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.

Known human anti-mouse antibodies



  • UCSF accepting new patients
    San Francisco California 94158 United States
  • Children's Hospital Los Angeles accepting new patients
    Los Angeles California 90027 United States

Lead Scientist at UCSF

  • Julia Chu, MD
    Assistant Professor, Pediatrics, School of Medicine. Authored (or co-authored) 7 research publications. Research interests: Myeloid leukemias · myelodysplastic syndrome · Primary Immune Deficiencies (PID) · Primary Immune Regulatory Disorders (PIRD)


accepting new patients
Start Date
Completion Date
New York Medical College
Phase 2 research study
Study Type
Expecting 20 study participants
Last Updated